0KF3 enters the post-earnings stretch with a double beat already on the board and a pivotal IND submission approaching — but the borrow market tells its own story of persistent scepticism.
Palatin's Q3 fiscal 2026 results, reported on May 13, came in well ahead of consensus. EPS of -$0.37 beat the -$1.26 estimate by a wide margin. Revenue of $3.9 million crushed the $1.3 million forecast. The driver was a revenue recognition event tied to the sublicensing of PL-9643 to Altanispac Labs, completed in January 2026 for $3.8 million upfront. Cash runway now extends to June 2027, removing the near-term funding cliff that had weighed on the stock. The share price had already signalled something was coming — up 11.4% on the week and 11.7% over the month, closing at $21.44.
The borrow market reflects sustained short interest that has been building quietly for months. Availability of shares to borrow is tight at 41.2% of short interest — meaning fewer than half as many shares are available to lend as are already out on loan. Short interest has crept up steadily from 2.74% of the free float in early April to 2.78% now: not extreme in absolute terms, but directionally consistent. Cost to borrow eased to 9.0% on May 12 from a mid-week spike of 15.7% on May 11, a move that likely reflects some short covering or position reshuffling around the earnings release itself. The broader borrow-cost picture over the past month is striking — a 335% increase since mid-April, from a trough below 3% in early April to a peak near 16% at the start of May. That kind of range signals a contested, actively repriced lending market, not a passive background.
Factor scores show a more mixed picture beneath the surface. The utilization rank sits in the 7th percentile — meaning Palatin's lending pool is more fully utilised than the vast majority of stocks in the universe. The DTC rank at the 18th percentile and the short score rank at the 25th percentile both confirm this is a name where the bearish side has meaningful structural presence, even if it is not at extremes. The ORTEX short score of 57.6 has edged higher every single day for two weeks, its tenth consecutive daily rise. That kind of steady grind higher in the short score, even as the price rallied, points to shorts holding their ground rather than fleeing into the earnings catalyst.
Institutional ownership is heavily concentrated in specialist biotech money. Driehaus Capital (9.4%), Logos Global (7.9%), Janus Henderson (7.9%) and Point72 (6.5%) together account for roughly a third of shares, all last reported as of December 31, 2025. AuGC Partners filed a Schedule 13G on April 23, 2026, holding 5.3% — a fresh disclosure that adds a newer name to the register. CEO Carl Spana and CFO Steve Wills both appear in the top ten holders with 3.6% and 3.6% respectively, though both made small open-market sales in late December 2025 at prices around current levels, trades carrying significance scores of just 1 out of 10.
The next catalyst is the one the call itself framed most clearly: an IND submission for Palatin's once-weekly MC4R selective peptide agonist, targeting Q4 calendar 2026. The oral small molecule program is tracking for an IND in H1 2027, with management pointing to improved MC4R selectivity and reduced hyperpigmentation risk as the clinical differentiator. The prior earnings report in February 2026 saw the stock jump 13.2% on the day and 37.5% over five days — the largest recorded reaction in the available history. Whether the borrow-side scepticism and the steadily rising short score reflect pipeline risk, dilution concern, or simple positioning into a volatile small-cap will become clearer as the IND timeline approaches.
See the live data behind this article on ORTEX.
Open 0KF3 on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
